Results 271 to 280 of about 20,100 (304)

Eculizumab use in kidney transplantation

Current Opinion in Organ Transplantation, 2015
Eculizumab suppresses the effector functions of the complement system and represents a therapeutic breakthrough for patients with paroxysmal nocturnal hemoglobinuria or atypical hemolytic uremic syndrome (aHUS). Safety monitoring is ongoing; so far, most notable is the expected increase in infection risk with encapsulated organisms.
Christopher K. Johnson, Nicolae Leca
openaire   +3 more sources

Clinical Effects of Eculizumab in PNH: Extravascular Hemolysis After Eculizumab Treatment

2017
The most important advance in the management of paroxysmal nocturnal hemoglobinuria (PNH) has been the introduction of eculizumab, a human monoclonal antibody against the C5 component of complement, that abrogates intravascular hemolysis by preventing the formation of the complement membrane attack complex.
Antonio M. Risitano, Rosario Notaro
openaire   +3 more sources

Starting eculizumab as rescue therapy in refractory myasthenic crisis

Neurological Sciences, 2023
C. Vinciguerra, L. Bevilacqua, A. Toriello, A. Iovino, G. Piscosquito, G. Calicchio, P. Barone   +6 more
semanticscholar   +1 more source

Eculizumab for paroxysmal nocturnal haemoglobinuria

The Lancet, 2009
The complement system plays a central part in both innate and acquired immunity, but the contribution of complement activation to pathobiology is largely ancillary. An exception to the non-dominant role of complement in disease is the haemolytic anaemia of paroxysmal nocturnal haemoglobinuria (PNH).
openaire   +3 more sources

Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan

International journal of hematology, 2023
J. Nishimura, T. Kawaguchi, Shuichi Ito, H. Murai, Akihiko Shimono, Takahisa Matsuda, Yuji Fukamizu, H. Akiyama, H. Hayashi, T. Nakano, S. Maruyama   +10 more
semanticscholar   +1 more source

Pegcetacoplan versus Eculizumab in PNH

New England Journal of Medicine, 2021
Gurnari, Carmelo, Pagliuca, Simona, Maciejewski, Jaroslaw P   +2 more
openaire   +6 more sources

Eculizumab in a Patient with Dense-Deposit Disease

New England Journal of Medicine, 2012
This letter indicates that in a patient with long-standing dense-deposit disease, a variant of membranoproliferative glomerulonephritis, eculizumab can be useful in the resolution of the nephrotic syndrome.
E. Daina, M. Noris, G. Remuzzi
openaire   +2 more sources

Comment on “Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab” [PDF]

Clinical Pharmacokinetics, 2020
Jialing Liu, Aliza Anwar Memon, Lingna Lyu, Lingna Lyu, Andrew M. Siedlecki   +4 more
openaire   +2 more sources

Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement

Pediatric nephrology (Berlin, West), 2023
D. Wildes, Susan Harvey, C. Costigan, C. Sweeney, E. Twomey, A. Awan, K. Gorman   +6 more
semanticscholar   +1 more source

Eculizumab [PDF]

Der Nephrologe, 2012
openaire   +1 more source